Caris Life Sciences (CAI)
Health Care · molecular diagnostics · NASDAQ
Caris Life Sciences delivers comprehensive molecular profiling and precision medicine insights to optimize oncology treatment and drug development.
What Caris Life Sciences does
Caris Life Sciences provides molecular information services and precision medicine solutions primarily for oncology. The company captures, aggregates, and analyzes molecular information to assist physicians with treatment decisions and support biopharmaceutical partners in therapeutic development and clinical programs.
Themes: precision medicine, oncology diagnostics, molecular diagnostics, biopharma research services
Fundamentals
- Price$27.50 as of 2026-10-08 close
- Market cap$7.8B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-16.5% 2025-10-08 close $32.95 → 2026-10-08 close $27.50
- P/E74.97 as of 2026-10-08
- Net margin-8.4% FY2025, SEC XBRL
- ROE-11.8% FY2025, SEC XBRL
- Debt / equity0.66 as of 2026-09-03
- Revenue growth (YoY)+38.5% as of 2026-09-03
- Revenue CAGR (3y)+62.9% SEC XBRL
- Beta1.27 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CAI compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Caris Life Sciences looks technically
Caris Life Sciences (CAI) is trading 26.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day high about 11 trading days ago. It is 18.3% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 26.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +26.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.45 | $25.45 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.78 | $21.78 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 32.89. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal | 15 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 26.3% above | +26.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control | 35.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($25.87 to $32.89) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 23.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $33.66 | $33.66 |
|---|---|---|
| From the 52-week high | it is 18.3% below its 52-week high (its highest price of the past year) | -18.3% |
| Above the 52-week low | it is 93.8% above its 52-week low (its lowest price of the past year) | +93.8% |
| Below the 52-week high | it is 18.3% below its highest point of the past year | 18.3% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $42.50 (set on 2025-08-22) | $42.50 |
| Given back of the 52-week move | over the past year its closes ranged ($14.55 to $32.95), and it has recovered well over two thirds of its fall from last year’s high — 70% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.92 to $26.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 70.4% |
| From the all-time high | it is 35.3% below its all-time high | -35.3% |
| Nearest price level | it is trading 2.8% below a resistance level at $28.26 — a price it turned at twice since 2025-09-25, most recently on 2026-08-25. Since 2025-06-18 it has 4 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $14.19 (set on 2026-05-13) | $14.19 |
| Above the all-time low | it is 93.8% above its all-time low | +93.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.78 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.78 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $25.09 and $33.81 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $25.09 – $29.45 – $33.81 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges above its 200-day average price (26.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.3% since the prior reading | +3.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Open gap | it gapped 4.5% above the previous close 35 sessions ago and has not traded back through the level it left behind at 20.97 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.5% |
| Gap filled | a 2.9% gap up opened on 2026-09-22 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.8 percentage points (the stock gained 10.8% while the market gained 1.0%) | +9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 54.9 percentage points (the stock gained 58.8% while the market gained 3.8%) | +55.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 27.2 percentage points (the stock gained 44.7% while the market gained 17.5%) | +27.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 31.5 percentage points (the stock lost 16.5% while the market gained 15.0%) | -31.5% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.9% of the share price. | +16.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $21.92 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | +25.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $26.26 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | +4.7% |
Price levels it has turned at before
CAI last closed at $27.50 on 2026-10-08. Since 2025-06-18 it has turned at 4 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $28.26 | Resistance | 2.8% above the last close | turned there twice · 2025-09-25 to 2026-08-25 |
| $29.08 | Resistance | 5.8% above the last close | turned there five times · 2025-10-14 to 2026-01-07 |
| $25.48 | Support | 7.4% below the last close | turned there twice · 2025-07-07 to 2025-12-15 |
| $23.03 | Support | 16.3% below the last close | turned there twice · 2025-11-07 to 2026-09-10 |
| $33.14 | Resistance | 20.5% above the last close | turned there three times · 2025-07-17 to 2026-09-23 |
| $19.89 | Support | 27.7% below the last close | turned there three times · 2026-03-25 to 2026-06-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $32.89.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$29.08 range $22.00 – $38.00; median $28.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CAI
- Consensus EPS estimate$0.02214 next reporting period, as of 2026-10-07
- Estimate change, 30 days-$0.00747 from $0.02961, on 2026-09-02, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on third-party payer reimbursement and coverage decisions","regulatory requirements including potential FDA oversight of laboratory developed tests","material weaknesses in internal control over financial reporting"]
What changed in the latest 10-Q
AI-assisted comparison of CAI's 10-Q filed 2026-08-05 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) adds that during the second quarter of 2026 the company expanded its Precision Whole Genome Platform with the launch of Caris Detect, a multi-cancer early detection blood test using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence.
- Newer filing (2026-08-05) adds that during the second quarter of 2026 the company commercially launched Caris ChromoSeq, a combined WGS and WTS assay for comprehensive genomic evaluation of myeloid malignancies from a single bone marrow aspirate or peripheral blood sample.
- Newer filing (2026-08-05) adds that during the second quarter of 2026 the company launched Caris MI Clarity, its first commercially available digital, AI/ML-based prognostic solution using computational pathology and machine learning on digitized H&E whole-slide images with clinical inputs to assess recurrence risk for early-stage breast cancer.
- Newer filing (2026-08-05) states tests have been run on over 1,130,000 cases as of June 30, 2026.
- Newer filing (2026-08-05) states the company believes its dataset now also serves as the foundation for digital solutions such as Caris MI Clarity.
- Newer filing (2026-08-05) references the commercial launches of Caris ChromoSeq, Caris Detect, and Caris MI Clarity in the second quarter of 2026 as expected contributors to growth.
- Removed:
- Older filing (2026-05-08) contained a paragraph stating that for the three months ended March 31, 2026 and 2025, total revenue was $216.2 million and $120.9 million, net loss was $0.5 million and $102.6 million, Adjusted EBITDA was $26.2 million and $(36.2) million, cash flow from operations was $32.9 million and $(31.3) million, free cash flow was $22.5 million and $(34.0) million, and cash/restricted cash/marketable securities were $825.7 million with $400.0 million principal debt outstanding as of March 31, 2026.
- Older filing (2026-05-08) stated tests had been run on over 1,070,000 cases as of March 31, 2026.
- Older filing (2026-05-08) described the company as a 'leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer' with expansions including cardiology, neurology, and metabolic conditions via the Caris Assure Platform feedback loop.
- Reworded:
- Newer filing (2026-08-05) opens the Overview describing the company as 'a leading TechBio company', while the older filing (2026-05-08) described it as 'a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer'.
- Newer filing (2026-08-05) states the company has spent the last 18 years developing and building its portfolio as of June 30, 2026, with 'over 1,130,000 cases', whereas the older filing (2026-05-08) stated 'over 1,070,000 cases as of March 31, 2026'.
- Newer filing (2026-08-05) abbreviates artificial intelligence and machine learning as 'AI and ML' immediately, whereas the older filing (2026-05-08) initially defined them as 'artificial intelligence ("AI") and machine learning ("ML") technologies'.
- Newer filing (2026-08-05) states 'increased testing volumes and the continued expansion of our menu of molecular profiling and digital solutions' will contribute to growth, whereas the older filing (2026-05-08) stated 'increased profiling volumes' would contribute to growth.
- Newer filing (2026-08-05) adds discussion of Caris MI Clarity to the dataset sentence, whereas older filing (2026-05-08) ended that sentence without the digital solutions reference.
- Newer filing (2026-08-05) includes additional detail about product launches in the third paragraph of the Molecular Intelligence portfolio description, whereas the older filing (2026-05-08) did not include product-specific launch descriptions at that point.
- Notes:
- The newer MD&A source is truncated at '...informing our blood-based bioinformatics algorithms, al' so content after that point could not be compared.
- Comparison is limited to the MD&A overview sections provided; financial condition and results of operations sections beyond the overview were not included in either source.
Risk Factors
- Added:
- Added a new subsection 'Purchases of Equity Securities by the Issuer and Affiliated Purchasers' under Item 2 in the newer filing (filed 2026-08-05), including a share repurchase activity table for the three months ended June 30, 2026, showing 1,000,000 shares purchased in June 2026 at an average price of $17.91 per share.
- Added a footnote stating the company maintains a share repurchase program authorized by the Board and announced on June 8, 2026, with approximately $82,097 (in thousands) maximum dollar value remaining.
- Added a note that average price paid per share excludes the 1% excise tax on net share repurchases required by the Inflation Reduction Act of 2022.
- Added 'Termination of Amended and Restated Investors' Rights Agreement' discussion under Item 5 in the newer filing, stating that effective August 4, 2026, the Company entered into a Termination Agreement terminating the Investors' Rights Agreement dated April 1, 2025, except certain limited indemnification provisions.
- Added disclosure in the newer filing that the Investors' Rights Agreement is filed as Exhibit 4.3 to the Annual Report on Form 10-K for the year ended December 31, 2025.
- Changed the fiscal quarter referenced in the Disclosure of Trading Arrangements from March 31, 2026 to June 30, 2026.
- Added Exhibit 10.1 described as 'First Amendment to Financing Agreement, dated as of June 7, 2026' in the newer filing's exhibit list.
- Removed:
- Removed Exhibit 10.1 described as 'Financing Agreement, dated as of April 1, 2026' from the older filing's exhibit list.
- Removed Exhibit 10.2 described as 'Caris Life Sciences, Inc. Annual Incentive Plan' from the older filing's exhibit list.
- Removed Exhibit 10.3 described as 'Executive Employment Agreement, dated as of August 2, 2022, by and between Caris Science, Inc. J. Russel Denton' from the older filing's exhibit list.
- Removed the redaction footnote for Exhibit 10.1 in the older filing, which stated 'Certain portions of this exhibit (indicated by "[***]") have been redacted pursuant to Regulation S-K, Item 601(b)(10).'
- Removed the footnote indicating a management contract or compensatory plan or arrangement for Exhibits 10.2 and 10.3 in the older filing.
- Reworded:
- The newer filing's signature date block changed from May 08, 2026 to August 05, 2026.
- The page number at the Table of Contents break following the Use of Proceeds section changed from 39 (older) to 44 (newer).
- Notes:
- The provided texts appear to contain the full Item 1A Risk Factors boilerplate, which is identical between the two filings, but the bulk of the 'Risk Factors' section is incorporated by reference from the Annual Report on Form 10-K and not reproduced in either source text provided.
- The newer filing's signatures section appears truncated at 'Principal Financial and Accou' in the provided text.
- This comparison is based solely on the two source texts provided and does not include any materiality or legal conclusions.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($12M) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 5 sells ($27M) — 3 selling insiders
- Last 180 days · read to 2026-10-042 buys ($1M) · 5 sells ($27M) — 2 buying, 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-22. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CAI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CAI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 39,035,534
- Reported value $695,647,383
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CAI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CAI had 13,331,431 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CAI had 4.72% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.01 days to cover at the same settlement.
- Reported short interest (shares) 13,331,431
- Short interest (% of shares outstanding) 4.72%
- Prior settlement (shares) 13,684,372
- Reported change -2.58%
- Days to cover (reported) 3.01
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Illumina (ILMN)
- Foundation Medicine (subsidiary of Roche)
- Tempus AI (TEM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CAI vs…
Caris Life Sciences is found in…
Frequently asked questions
What does Caris Life Sciences (CAI) do?
Caris Life Sciences provides molecular information services and precision medicine solutions primarily for oncology. The company captures, aggregates, and analyzes molecular information to assist physicians with treatment decisions and support biopharmaceutical partners in therapeutic development and clinical programs.
What sector is Caris Life Sciences (CAI) in?
Caris Life Sciences (CAI) is classified in the Health Care sector. Its industry is molecular diagnostics. It trades on NASDAQ.
Who are Caris Life Sciences's (CAI) competitors?
Notable peers of Caris Life Sciences (CAI) include Exact Sciences, Guardant Health, Illumina, Foundation Medicine (subsidiary of Roche) and Tempus AI. This peer set is informational only — not financial advice.
Is Caris Life Sciences (CAI) overbought or oversold right now?
Caris Life Sciences (CAI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CAI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.